A significant opinion by the U.S. Court of Appeals for the First Circuit is expected to bolster a defense argument that judges shouldn’t grant certification of class actions with uninjured class members.

William Kayatta Jr., a judge on the First Circuit, wrote on Oct. 15 that a federal district judge should not have granted certification of a class action alleging antitrust violations over the anti-inflammatory prescription drug Asacol.